Copyright
©The Author(s) 2024.
World J Hepatol. Oct 27, 2024; 16(10): 1151-1157
Published online Oct 27, 2024. doi: 10.4254/wjh.v16.i10.1151
Published online Oct 27, 2024. doi: 10.4254/wjh.v16.i10.1151
Ref. | Study design | Drug/duration | HBV patients number | Baseline cirrhosis | Main results |
Fontana et al[18], 2002 | Prospective | Lamivudine for 16 months | 154 | 154 (DC) | 78% had very high mortality due to complications of liver failure |
Dienstag et al[38], 2003 | Prospective | Lamivudine, 3 years | 63 | 11 | Cirrhosis regressed in 8 of 11 patients (73%) |
Hadziyannis et al[37], 2006 | Prospective | Adefovir, up to 240 weeks | 125 | 4 | 58% had reversal of bridging fibrosis/cirrhosis; 3 had cirrhosis reversal |
Schiff et al[39] 2008 | Randomized | Entecavir/lamivudine for 48 weeks | 1633 | 245 | 71% of Entecavir and 61.5% of lamivudine group showed fibrosis regression |
Das et al[40], 2010 | Retrospective-prospective | Lamivudine/adefovir | 151 | 151 (DC) | Better 5 year survival rate in treated patients for > 6 months |
Andersen et al[41], 2011 | Prospective | Nucleoside(tide) analogues, 50.5 months | 66 | 53 | 26 (49%) had regression of cirrhosis |
Marcellin et al[9], 2013 | Randomized | TDF/adefovir for 48 weeks then open-label TDF | 641 | 96 | 71 of 96 (74%) became non-cirrhotic at 5 years |
Du et al[42], 2013 | Prospective | Lamivudine/adefovir for 44.5 months | 48 | 33 | 23 (69%) patients had reversal of cirrhosis |
Srivastava et al[43], 2013 | Prospective | TDF 2 years | 96 | 96 (DC) | MELD score of > 20 a/w 58 fold increased mortality |
Papatheodoridis et al[16], 2018 | Multicenter prospective | TDF/entecavir for 6 years | 1951 | 526 | Significant improvement in overall survival |
Hsu et al[13] 2021 | Randomized | TDF for 3 years | 73 | 00 | 16%- reduced fibrosis, 58% non- progression |
Desalegn et al[44], 2019 | Prospective | TDF for 2 years | 276 | 35 (DC) | 24 fold increase in mortality if decompensated cirrhosis |
Ismael et al[3], 2024 | Prospective | TDF | 193 | 35 (DC) | 60% of all death occurred due to decompensated liver disease with in first 6 months |
- Citation: Marrapu S, Kumar R. Chronic hepatitis B: Prevent, diagnose, and treat before the point of no return. World J Hepatol 2024; 16(10): 1151-1157
- URL: https://www.wjgnet.com/1948-5182/full/v16/i10/1151.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i10.1151